| Literature DB >> 26767365 |
Abstract
BACKGROUND: Recruitment to clinical trials is difficult with many trials failing to recruit to target and within time. Embedding trials of recruitment interventions within host trials may provide a successful way to improve this. There are no guidelines for reporting such embedded methodology trials. As part of the Medical Research Council funded Systematic Techniques for Assisting Recruitment to Trials (MRC START) programme designed to test interventions to improve recruitment to trials, we developed guidelines for reporting embedded trials.Entities:
Mesh:
Year: 2016 PMID: 26767365 PMCID: PMC4714476 DOI: 10.1186/s13063-015-1126-y
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Checklist of items for reporting embedded recruitment trials
| Section/topic and item no. | CONSORT 2010 (standard) checklist item | Extension for embedded recruitment trials |
|---|---|---|
| Title and abstract | ||
| 1a | Identification as a randomised trial in the title | Identification as an |
| 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) | Structured summary of |
| Introduction | ||
| Background and objectives | ||
| 2a | Scientific background and explanation of rationale | Scientific background and explanation of rationale for the |
| 2b | Specific objectives or hypotheses | Specific objectives or hypotheses for the |
| Methods | ||
| Trial design | ||
| 3a | Description of trial design (such as parallel, factorial) including allocation ratio | Description of |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | Important changes to methods of the |
| Participants | ||
| 4a | Eligibility criteria for participants | Eligibility criteria for participants for the |
| 4b | Settings and locations where the data were collected | Settings and locations where the |
| Interventions | ||
| 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | The interventions for each group |
| Outcomes | ||
| 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | Completely defined pre-specified primary and secondary outcome measures for the |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons | Any changes to |
| Sample size | ||
| 7a | How sample size was determined | How sample size for the |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | When applicable, explanation of any interim analyses and stopping guidelines for the |
| Randomisation | ||
| Sequence generation | ||
| 8a | Method used to generate the random allocation sequence | Method used to generate the random allocation sequence for the |
| 8b | Type of randomisation; details of any restriction (such as blocking and block size) | Type of randomisation; details of any restriction (such as blocking and block size) in the |
| Allocation concealment mechanism | ||
| 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | Mechanism used in the |
| Implementation | ||
| 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions? | Who generated the random allocation sequence(s), who enrolled participants, and who assigned participants to |
| Blinding | ||
| 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how? | If done, who was blinded after assignment to |
| 11b | If relevant, description of the similarity of interventions | If relevant, description of the similarity of interventions in the |
| Statistical methods | ||
| 12a | Statistical methods used to compare groups for primary and secondary outcomes | Statistical methods used to compare groups for primary and secondary outcomes of the |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | Methods for additional analyses, such as subgroup analyses and adjusted analyses for the |
| Results | ||
| Participant flow (a diagram is strongly recommended) | ||
| 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | For each group in the |
| 13b | For each group, losses and exclusions after randomisation, together with reasons | For each group, losses and exclusions after randomisation to the |
| Recruitment | ||
| 14a | Dates defining the periods of recruitment and follow-up | Dates defining the periods of recruitment and follow-up |
| 14b | Why the trial ended or was stopped | Why the |
| Baseline data | ||
| 15 | A table showing baseline demographic and clinical characteristics for each group |
|
| Numbers analysed | ||
| 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | For each group in the |
| Outcomes and estimation | ||
| 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95 % confidence interval) | For each primary and secondary outcome, results for each group in the |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | For binary outcomes in the |
| Ancillary analyses | ||
| 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | Results of any other analyses performed for the |
| Harms | ||
| 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | All important harms or unintended effects in each group |
| Discussion | ||
| Limitations | ||
| 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses |
|
| Generalisability | ||
| 21 | Generalisability (external validity, applicability) of the trial findings | Generalisability (external validity, applicability) |
| Interpretation | ||
| 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | Interpretation consistent with results |
| Other information | ||
| Registration | ||
| 23 | Registration number and name of trial registry | Registration number and name of trial registry |
| Protocol | ||
| 24 | Where the full trial protocol can be accessed, if available | Where the |
| Funding | ||
| 25 | Sources of funding and other support (such as supply of drugs), role of funders | For the |
Fig. 1Example abstract for an embedded recruitment trial [17]
Fig. 2Flow chart illustrating intervention and control sites and route of additional communication strategy
Fig. 3A flow chart illustrating the focal point(s) of the host trial recruitment pathway targeted by embedded recruitment trial interventions
Fig. 4Recruitment flowchart
Fig. 5Recruitment flowchart
Fig. 6Recruitment flowchart
Fig. 7CONSORT diagram showing the flow of participants through each stage of the randomised trial (enrolment, intervention allocation, follow-up and data analysis)
Characteristics of all participants (n = 703) [42]
| Intervention | Control | |
|---|---|---|
| ( | ( | |
| Mean age | 41.11 | 41.53 |
| (SD = 10.9) | (SD = 10.7) | |
| Gender | ||
| Male | 116 (32.6 %) | 104 (30.0 %) |
| Female | 240 (67.4 %) | 243 (70.0 %) |
| Number of episodes of sick leave | ||
| One episode in the last 2 years | 168 (47.2 %) | 179 (51.6 %) |
| Two or more episodes in the last 2 years | 188 (52.8 %) | 168 (48.4 %) |
| Diagnosis | ||
| Mental health problems | 163 (45.8 %) | 160 (46.1 %) |
| Muscle-skeletal problems | 154 (43.3 %) | 147 (42.4 %) |
| Other diagnosis | 39 (11.0 %) | 40 (10.5 %) |
Effect of interventions on recruitment into host trial [35]
| Interventions | Recruitment in intervention group | Recruitment in control group | Difference in recruitment intervention minus control (95 % CI) adjusted for the clustering effect of household (395 households) | OR (95 % CI) for recruitment into study adjusted for clustering effect of household (395 households) |
|---|---|---|---|---|
| Telephone (groups 3 + 4 versus control (groups 1 + 2) | 134/280 (47.9 %) | 106/280 (37.9 %) | 10.0 % (0.2–19.8 %) | 1.5 (1.0–2.3) |
|
| ||||
| Questionnaire (groups 2 + 4) versus control (groups 1 + 3) | 116/280 (41.4 %) | 124/280 (44.3 %) | −2.9 % (−12.7–7.0 %) | 0.9 (0.6–1.3) |
|
|